Stromal MCT4 Expression Analysis for TNBC Patient Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers fail to accurately predict poor overall survival and treatment outcomes in triple-negative breast cancer patients, particularly in identifying high-risk groups that could benefit from MCT4 inhibitor treatment.
Innovation Solution
The method involves determining the expression levels of stromal MCT4 and Cav-1 in cancer tissue samples to classify patients as stromal MCT4-positive or negative, allowing for personalized treatment decisions and stratification of risk groups, with MCT4 inhibitors being proposed as a therapeutic option for aggressive breast cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current biomarkers are used to predict treatment outcomes in triple-negative breast cancer patients, then general prognostic information can be obtained, but accurate identification of high-risk groups that would benefit from MCT4 inhibitor treatment cannot be achieved
Solution Approach 1:
The patent segments the tumor stroma into distinct functional zones based on MCT4 expression levels, identifying MCT4-high and MCT4-low regions. This segmentation allows for precise identification of high-risk patient subgroups who would benefit from MCT4 inhibitor treatment, moving beyond general biomarker assessment to targeted prediction.
Solution Approach 2:
The patent applies local quality analysis by examining MCT4 expression specifically in the stromal compartment rather than uniformly across the entire tumor. This localized approach reveals that stromal MCT4 expression is the critical predictor of treatment response, enabling accurate identification of patients who will respond to MCT4 inhibitors while avoiding unnecessary treatment in non-responders.
2Measurement precision
If stromal MCT4 expression is measured to identify high-risk patients, then accurate prognostic assessment and treatment stratification can be achieved, but additional testing complexity is introduced
Solution Approach 1:
The patent demonstrates that MCT4 expression analysis serves multiple functions simultaneously: it provides prognostic information, predicts treatment response to MCT4 inhibitors, and enables patient stratification for clinical trials. This multi-functionality justifies the additional testing by delivering comprehensive clinical utility from a single measurement.
Solution Approach 2:
The patent uses MCT4 expression level as an intermediary biomarker that connects tumor stroma metabolism to clinical treatment outcomes. By measuring this intermediary marker, the system translates complex metabolic states into actionable prognostic information without requiring direct measurement of metabolic flux or treatment response.
Data Source
AI summary
This invention provides a method of identifying one or more subgroups of cancer patients that are likely to benefit from treatment with a monocarboxylate transporter (MCT) protein inhibitor comprising: (a) obtaining a sample of a cancer/tumor tissue from each of said cancer patients; (b) determining the expression level of stromal MCT4 protein in each of said samples of cancer/tumor tissue to obtain a first dataset; and (c) using the expression level of the stromal MCT4 protein from said first dataset to classify each of said sets of one or more cancer patients as stromal MCT4-positive or stromal MCT4-negative, wherein the cancer patients classified as stromal MCT4-positive are patients that are more likely to benefit from treatment with said MCT protein inhibitor. This invention also provides related methods for treating a cancer/tumor whose stromal component expresses the MCT4 protein in a patient.